

IMMUNOMEDICS TO PROVIDE CLINICAL TRIAL UPDATES ON SOLID-TUMOR ANTIBODY-DRUG CONJUGATES AT CANCER CONFERENCE

Morris Plains, NJ, March 31, 2014 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 – 9, 2014.

Two of the poster presentations will provide updates on the clinical trials of IMMU-132 and IMMU-130, the Company's antibody-drug conjugates (ADCs) that are in Phase II clinical trials for patients with solid tumors and metastatic colorectal cancer, respectively. In addition, results from a preclinical study aimed at understanding why patients who were refractory to prior therapy with topoisomerase I inhibitors, such as irinotecan, yet responded to our ADCs will be reported. Finally, the development of a novel T-cell redirecting immunotherapeutic agent targeting the TROP-2 antigen in pancreatic and gastric cancers will be described.

The schedule and meeting places for the poster sessions, together with the abstract number, poster section and poster board numbers, are listed below:

- “SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results” [Abstract No. CT206, Session Title: Early Phase Clinical Trials 1: Phase I, Monday, April 7, 8:00 a.m. – 12:00 p.m., Hall A-E, Poster Section 38, Poster Board Number 6]
- “IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies” [Abstract No. CT211, Session Title: Early Phase Clinical Trials 1: Phase I, Monday, April 7, 8:00 a.m. – 12:00 p.m., Hall A-E, Poster Section 38, Poster Board Number 11]
- “SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science” [Abstract No. 2904, Session Title: Prophylactic and Therapeutic Immune-based Therapies, Monday, April 7, 1:00 p.m. – 5:00 p.m., Hall A-E, Poster Section 39, Poster Board Number 26]
- “A novel Trop-2/CD3 trivalent bispecific antibody effectively redirects T cells to kill target human pancreatic and gastric cancer cells” [Abstract No. 2655, Session Title: New Antibodies and Antibody Drug Conjugates, Monday, April 7, 1:00 p.m. – 5:00 p.m., Hall A-E, Poster Section 31, Poster Board Number 16]

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer,

~ more ~

autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, clivatuzumab tetraxetan labeled with a radioisotope is in a Phase III pivotal trial in advanced pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development include 2 antibody-drug conjugates, IMMU-132 (anti-TROP-2-SN-38) and IMMU-130 (anti-CEACAM5-SN-38). We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. We believe that our portfolio of intellectual property, which includes approximately 245 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-4 ranking in the January 2014 Patent Board scorecard in the Biotechnology industry. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company’s control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:

Dr. Chau Cheng
Senior Director, Investor Relations & Grant Management
(973) 605-8200, extension 123
ccheng@immunomedics.com